DARZALEX Q2 Sales Hit $4.2B, Up 46% YoY, Boosting Genmab Royalties
GMAB sits 38% above its 52-week low of $20.995.
Summary
Genmab reported worldwide net sales of DARZALEX (daratumumab) of $4.207 billion in Q2 2026, a 46% increase from $2.88 billion in Q2 2025. U.S. sales were $2.435 billion and rest-of-world $1.772 billion. Genmab earns royalties on these sales from Johnson & Johnson. This follows strong Q1 2026 revenue growth and recent positive epcoritamab data, reinforcing the royalty stream's upward trajectory. The sales beat consensus estimates of ~$3.8 billion, signaling continued market expansion and potential for higher royalty income. Next catalyst: Genmab's Q2 2026 financial results, where royalty revenue will be disclosed.
At the time of this announcement, GMAB was trading at $28.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $21.00 to $35.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.